Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Inhibikase Therapeutics (IKT) over the last 3 years, with Q3 2022 value amounting to $23683.0.

  • Inhibikase Therapeutics' Current Deferred Revenue changed N/A to $23683.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $23683.0, marking a year-over-year change of. This contributed to the annual value of $2.3 million for FY2020, which is N/A changed from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Current Deferred Revenue of $23683.0 as of Q3 2022.
  • In the past 5 years, Inhibikase Therapeutics' Current Deferred Revenue registered a high of $2.3 million during Q4 2020, and its lowest value of $23683.0 during Q3 2022.
  • In the last 3 years, Inhibikase Therapeutics' Current Deferred Revenue had a median value of $142619.0 in 2021 and averaged $753415.2.
  • Over the last 5 years, Inhibikase Therapeutics' Current Deferred Revenue had its largest YoY gain of 8339.35% in 2022, and its largest YoY loss of 8339.35% in 2022.
  • Inhibikase Therapeutics' Current Deferred Revenue (Quarter) stood at $2.3 million in 2020, then tumbled by 93.87% to $142619.0 in 2021, then plummeted by 83.39% to $23683.0 in 2022.
  • Its Current Deferred Revenue was $23683.0 in Q3 2022, compared to $23684.0 in Q2 2022 and $142619.0 in Q2 2021.